Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of ADS-5102 for levodopa-induced dyskinesia in Parkinson's disease
2014-003739-20Phase 3Completed
- Sponsor
- Adamas Pharmaceuticals, Inc.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amantadine in Parkinson's disease (PD) and levodopa-induced dyskinesia (LID), sponsored by Adamas Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability of ADS-5102. Started Jan 2015; status: completed.
02
Drugs
amantadine
03
Conditions
Parkinson's disease (PD)levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on 2014-003739-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003739-20.